Generic placeholder image

Current Drug Targets - CNS & Neurological Disorders

Editor-in-Chief

ISSN (Print): 1568-007X
ISSN (Online): 1568-007X

Repinotan, A 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke

Author(s): Helmi L. Lutsep

Volume 4 , Issue 2 , 2005

Page: [119 - 120] Pages: 2

DOI: 10.2174/1568007053544165

Price: $65

Abstract

Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5- HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Keywords: Infarct, ischemia, acute stroke treatment, neuroprotection, neuroprotectant, repinotan


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy